Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ishares Msci Thailand Etf — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224.08 (market cap $29.60B), while Ishares Msci Thailand Etf trades at $73.34. The key difference: Ishares Msci Thailand Etf is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | THD | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $75.05 |
52-Week Low | $205.48 | $56.41 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
THD trades at $73.34, down 0.49% on the day, with a bullish technical outlook supported by moving averages and a neutral stance from oscillators. The stock's recent performance is influenced by its exposure to AI hardware through holdings like Delta Electronics, contributing to strong returns. Recent news highlights foreign capital shifts in Asian equities, with Thailand benefiting from selective investor interest amid semiconductor-driven volatility.
The outlook for THD hinges on sustained AI-driven growth and regional economic stability, but risks include overreliance on tech sectors and macroeconomic headwinds. Investor sentiment is cautiously optimistic, with technical strength suggesting potential upside if fundamental support holds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
